Muscle Relaxants and Antispasticity Agents

Physical Medicine and Rehabilitation Clinics of North America

Volumn 17, Issue 2, 2006, Pages 401-413

  Meleger, Alec L ^a  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTISPASTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARISOPRODOL; CENTRAL MUSCLE RELAXANT; CHLORPHENESIN; CLONAZEPAM; CLONIDINE; CYCLOBENZAPRINE; DANTROLENE; DIAZEPAM; FLUPIRTINE; LORAZEPAM; MEPHENESIN; MEPROBAMATE; METAXALONE; METHOCARBAMOL; MUSCLE RELAXANT AGENT; ORPHENADRINE; OXAZEPAM; PLACEBO; QUININE; TEMAZEPAM; TETRAZEPAM; TIZANIDINE; TOLPERISONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGITATION; ANALGESIA; ANGINA PECTORIS; ANOREXIA; ANXIETY DISORDER; APLASTIC ANEMIA; ASTHMA; ATAXIA; BACKACHE; BLURRED VISION; BONE MARROW SUPPRESSION; BOTULISM; BRADYCARDIA; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPRESSION; DIARRHEA; DIPLOPIA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DROWSINESS; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DYSPHONIA; EMOTIONAL DISORDER; ENZYME BLOOD LEVEL; EOSINOPHILIA; ERECTILE DYSFUNCTION; ERYTHEMA; ERYTHEMA MULTIFORME; EUPHORIA; FATIGUE; FIBROMYALGIA; GENERAL ANESTHESIA; HALLUCINATION; HEARING LOSS; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; IMPOTENCE; INSOMNIA; JAUNDICE; LEUKOPENIA; LIBIDO DISORDER; LIVER FAILURE; LIVER TOXICITY; META ANALYSIS; MICTURITION DISORDER; MOTOR DYSFUNCTION; MUSCLE RELAXATION; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; MYOFASCIAL PAIN; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; NEUROLOGICAL COMPLICATION; NEUROPATHOLOGY; NEUROPHARMACOLOGY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PERICARDITIS; PLEURA EFFUSION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RESPIRATORY FAILURE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SPASTICITY; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TRIGGER POINT; URINE DISCOLORATION; URINE RETENTION; VASCULITIS; XEROSTOMIA;

ADULT; AGED; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; MUSCULAR DISEASES; NEUROMUSCULAR DEPOLARIZING AGENTS; PAIN; PAIN MEASUREMENT; PROGNOSIS; TREATMENT OUTCOME;

EID: 33645979707     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2005.12.005     Document Type: Review

References (25)

1. Skootsky S.A., Jaeger B., and Oye R.K. Prevalence of myofascial pain in general internal medicine practice. West J Med 151 (1989) 157-160
2. McGuire J.R., and Harvey K.L. The prevention and management of complications after stroke. Phys Med Rehabil Clin North Am 10 (1999) 857-874
3. MS Society. MS symptom management survey (1997), MS Society, London
4. Maynard F.M., Karunas R.S., and Waring W.P. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil 71 (1990) 566-569
5. Di Iorio D., Henley E., and Doughty A. A survey of primary care physician practice patterns and adherence to acute low back problem guidelines. Arch Fam Med 9 10 (2000) 1015-1021
6. Cherkin D.C., Wheeler K.J., Barlow W., et al. Medication use for low back pain in primary care. Spine 23 5 (1998) 607-614
7. 2-Messung in der verspannten Ruckenmuskulatur (m. erector spinae). Z Rheumatol 49 (1990) 208-216
8. Mense S., Simons D.G., and Russell I.J. Muscle pain: understanding its nature, diagnosis, and treatment (2001), Lippincott Williams & Wilkins, Baltimore p. 7-15, 255
9. Kobayashi H., Hasegawa Y., and Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol 311 1 (1996) 29-35
10. Borenstein D.G., and Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther 25 4 (2003) 1056-1073
11. Thomson Micromedex. 1974-2005. Available at: http://www.micromedex.com. Accessed February 5, 2006.
12. Hwang A.S., and Wilcox G.L. Baclofen, gamma-aminobutyric acid B receptors and substance P in the mouse spinal cord. J Pharmacol Exp Ther 248 (1989) 1026-1033
13. Tulder M.W., Touray T., Furlan A.D., et al. Muscle relaxants for non-specific low-back pain. Cochrane Database Syst Rev 3 (2005)
14. Browning R., Jackson J.L., and O'Malley P.G. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med 161 13 (2001) 1613-1620
15. Basmajian J.V. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: two double-blind controlled clinical and laboratory studies. Arch Phys Med Rehabil 59 (1978) 58-63
16. Bercel N.A. Cyclobenzaprine in the treatment of skeletal muscle spasm in osteoarthritis of the cervical and lumbar spine. Curr Ther Res 22 (1977) 462-468
17. Brown Jr. B.R., and Womble J. Cyclobenzaprine in intractable pain syndromes with muscle spasm. JAMA 240 (1978) 1151-1152
18. Taricco M., Adone R., Pagliacci C., et al. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev 2 (2000) CD001131
19. Shakespeare D.T., Boggild M., and Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 4 (2003) CD001332
20. Coffey R.J., Cahill D., Steers W., et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long term multicenter study. J Neurosurg 78 (1993) 226-232
21. Semenchuk M.R., and Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain 1 4 (2000) 285-292
22. Kawamata T., Omote K., Yamamoto H., et al. Antihyperalgesic and side effects of intrathecal clonidine and tizanidine in a rat model of neuropathic pain. Anesthesiology 98 6 (2003) 1480-1483
23. Bartusch S.L., Sanders B.J., D'Alessio J.G., et al. Clonazepam for the treatment of lancinating phantom limb pain. Clin J Pain 12 1 (1996) 59-62
24. Bennett A. Comparison of cyclobenzaprine and placebo in the management of fibrositis. Arthritis Rheum 31 12 (1988) 1535-1542
25. Abeles M. Long-term effectiveness of orphenadrine citrate in the treatment of fibromyalgia. In: American College of Rheumatology Scientific Abstracts. 113-A270.